Overall, this exploratory analysis with machine learning algorithms suggested that blood CD34+/CD45dim/CD117+ cells might be associated with tumor resistance to both antiangiogenic and non-antiangiogenic therapies. The gene discussed is CD34; the disease is neoplasm.